Tel: 1-631-504-6093
Email:
Awesome Features1111

BTK inhibitor Velexbru approved new indications: treatment of two kinds of malignant lymphoma, the total remission rate is 90%

Ono Pharmaceutical recently announced that its BTK inhibitor Velexbru (tirabrutinib hydrochloride, 80mg tablet) has been approved in Japan for the treatment of Fahrenheit macroglobulinemia (WM) and lymphocytic lymphoma (LPL). Velexbru is a highly […]

Read More →

Heavy news for diabetes! Johnson & Johnson Invokana approved for use in patients with type 2 diabetes and diabetic nephropathy

Johnson & Johnson (JNJ) ‘s Janssen Pharmaceuticals has announced that Health Canada has approved a new indication for the glucose-lowering drug Invokana (canagliflozin): Complementary drugs for standard care therapies for […]

Read More →

p53 target new drug! Aprea’s Blood Cancer Combination Therapy Receives FDA Breakthrough Therapy Designation

Aprea Therapeutics is a Boston-based biopharmaceutical company focused on developing and commercializing innovative cancer therapies that reactivate the tumor suppressor protein p53. Recently, the company announced that the U.S. food […]

Read More →